Journal article
[CD34+ cell selection methods, quality controls and expected results: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
-
Calmels B
Centre de thérapie cellulaire, institut Paoli-Calmettes, 13009 Marseille, France.
-
Gautier É
EFS Île-de-France, unité d'ingénierie et de thérapie cellulaire, 94017 Créteil, France.
-
Magnani A
Hôpital Necker-Enfants Malades, laboratoire de thérapie cellulaire génique, 75015 Paris, France.
-
Magrin É
Hôpital Necker-Enfants Malades, laboratoire de thérapie cellulaire génique, 75015 Paris, France.
-
Mamez AC
Hôpitaux universitaires de Genève, laboratoire de thérapie cellulaire, 1211 Genève, Suisse.
-
Vaissié A
CHU de Lille, plateforme de biothérapies, 59000 Lille, France.
-
Yakoub-Agha I
Université de Lille, CHU de Lille, Infinite, U1286, Inserm, 59000 Lille, France.
-
Baudoux É
CHU de Liège, thérapie cellulaire, 4000 Liège, Belgique. Electronic address: e.baudoux@chuliege.be.
Show more…
Published in:
- Bulletin du cancer. - 2020
English
CD34+ immunomagnetic positive selection allows for CD34+ hematopoietic progenitors separation from CD3+ lymphocytes subsets, usually from an apheresis product collected from a previously mobilized donor. This T-cell depleted stem cell graft is primarily intended for rare cases (around 2% of allotransplanted patients in France) of severe, persistent, symptomatic bi- or tri-cytopenia post-allotransplantation, in order to allow for hematologic reconstitution without increasing the risk of GvHD occurrence. Although semi-manual and complex, the process is of sufficient robustness to consistently generate a cellular product with distinctive features and specifications, based on iterative in-process quality controls, that are discussed within these guidelines.
-
Language
-
-
Open access status
-
closed
-
Identifiers
-
-
Persistent URL
-
https://roar.hep-bejune.ch/global/documents/194602
Statistics
Document views: 9
File downloads: